Category: Investment, Biotech, Biodefense
Medical Technology Breaking News: SeeThruEquity Issues Company Note on Aethlon Medical (OTCBB:AEMD) and Increase Target Price to $0.52
Company Announces Collaboration with Boston University CTE Center and Expanded Hemopurifier Clinical Studies
Visit this company: www.aethlonmedical.com
New York, NY - October 7, 2014 (Investorideas.com newswire) SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company note on Aethlon Medical, Inc. (OTCBB:AEMD), medical device company focused on creating innovative devices that address unmet medical needs in cancer, infectious disease and other life-threatening conditions.
"Aethlon Medical's announcement that its diagnostic subsidiary Exosome Sciences has established a clinical collaboration with Boston University CTE Center is a validation of the company's exosome-based solutions for diagnosing diseases. As a result, we are raising our price target to $0.52 per share," stated Ajay Tandon, Chief Executive Officer of SeeThruEquity.
AEMD and ESI announce collaboration with CTE Center to advance diagnostic candidate to detect CTE
On September 26, 2014, Aethlon Medical and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), established a clinical collaboration with the Boston University (BU) CTE Center to advance a blood-based diagnostic candidate to detect Chronic Traumatic Encephalopathy (CTE), a progressive neurodegenerative disorder, in living individuals. Currently CTE can only be diagnosed through postmortem autopsy and was first found at autopsy in former National Football League (NFL) players. ESI develops exosome-based solutions to diagnose cancer and neurodegenerative disorders, and has successfully isolated exosome-based biomarkers transporting tau protein across the blood-brain barrier and into the circulatory system. As with various other diseases, CTE is characterized by excess accumulation of tau in the brain. As part of the collaboration, ESI researchers will evaluate and define exosome and exosomal tau populations in blood samples collected from participants (former NFL players and other athletes) enrolled in the DETECT (Diagnosing and Evaluating Traumatic Encephalopathy Using Clinical Tests) study. The DETECT study is the first research project on CTE funded by National Institutes of Health and focuses on developing blood-based tests for diagnosing CTE during life.
We believe the collaboration with the BU CTE Center validates ESI's exosome-based solutions for diagnosing diseases, and acts as a launch pad for developing future diagnostic tests for a variety of diseases. Although CTE is a rare condition occurring primarily in athletes and thereby limited market size in terms of number of tests, we expect AEMD to develop and launch tests for numerous cancer and neurological diseases over the next few years. We expect AEMD to launch diagnostic tests for CTE and other diseases in 2HFY15E.
AEMD expands Hemopurifier studies to include dengue virus
Another recent (Sept 24, 2014) important event post our release of initiation report was the announcement of an agreement with Qualtran, LLC, which expands human clinical studies of Hemopurifier therapy to include individuals infected with dengue virus, a global health threat not addressed with approved drug or vaccine therapies. With AEMD planning alternative FDA pathway for obtaining market approval by incorporating data from the proposed dengue treatment study into a Humanitarian Use Device (HUD) submission, we believe AEMD stands a good chance at getting approval for Hemopurifier for the Dengue indication. We note that AEMD is in the process of initiating the first FDA approved study of Hemopurifier(r) therapy in hepatitis c virus (HCV) patients.
The note is available here: AEMD Company Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will also be available on these platforms.
Please review important disclosures on our website at www.seethruequity.com.
About Exosome Sciences, Inc.
Exosome Sciences (ESI), a majority wholly owned subsidiary of Aethlon Medical, Inc., develops exosome-based solutions to improve identification and monitoring of acute and chronic conditions. Our candidate products are focused toward diagnostic advancements in the fields of oncology, infectious disease and brain injury. Exosomes represent an optimal diagnostic target as diseased or injured cells release these particles into body fluids such as urine, blood, saliva and cerebrospinal fluid where they can be accessed for analysis. Our exosome-based assays unlock the ability to identify proteomic and genomic alterations underlying a wide-range of pathologies, thus allowing for the introduction of novel non-invasive "liquid biopsies". Additional information can be found online at www.ExosomeSciences.com
About Aethlon Medical, Inc.
Aethlon Medical creates medical devices that target unmet therapeutic needs in infectious disease, cancer and neurodegenerative disorders. The company's lead product is the Aethlon Hemopurifier(R), a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. Additional information can be found online at www.AethlonMedical.com.
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.
For more information visit www.seethruequity.com.
James A. Joyce
Chairman and CEO
Chief Financial Officer
Get free news alerts: Sign up here
Disclaimer/ Disclosure: Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Disclosure: AEMD subscribes to the Investorideas newswire content publishing annual program (9700 per Year, paid quarterly) for news publishing.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.